Paper
0
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)
Authors
K. Yamazaki,Michitaka Nagase
Hiroo Tamagawa,Shinya Ueda,Takao Tamura,K. Murata,Takako Nakajima,Eishi Baba,Masahiro Tsuda,Toshikazu Moriwaki,Taito Esaki,Yasushi Tsuji,Kei Muro,Koichi Taira,Tadamichi Denda,Sadao Funai,Katsunori Shinozaki,Hitoshi Yamashita,Naotoshi Sugimoto,Tatsuya Okuno,Tomohiro Nishina,M. Umeki,Takayuki Kurimoto,Tetsuji Takayama,Akihito Tsuji,Miki Yoshida,A. Hosokawa,Yoshihiro Shibata,Koichi Suyama,Masaru Okabe,Koichi Suzuki,Narihito Seki,Kentaro Kawakami,Mikio Sato,Koshi Fujikawa,T. Hirashima,Takaya Shimura,K. Taku,Toshio Otsuji,Tamura Fumio,Eiji Shinozaki,Kazutaka Nakashima,Hiroki Hara,Takahiro Tsushima,Masahiko Ando,Satoshi Morita,Narikazu Boku,Ichinosuke Hyodo
+46 authors
,Kenichiro NakashimaJournal
Published
May 14, 2016
Show more
Save
Tip0
TipSave